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Tumor-associated stromal cells as key
contributors to the tumor
microenvironment
Karen M. Bussard1,2, Lysette Mutkus3, Kristina Stumpf3, Candelaria Gomez-Manzano4 and Frank C. Marini1,3*
Abstract
The tumor microenvironment is a heterogeneous population of cells consisting of the tumor bulk plus supporting
cells. It is becoming increasingly evident that these supporting cells are recruited by cancer cells from nearby
endogenous host stroma and promote events such as tumor angiogenesis, proliferation, invasion, and metastasis,
as well as mediate mechanisms of therapeutic resistance. In addition, recruited stromal cells range in type and
include vascular endothelial cells, pericytes, adipocytes, fibroblasts, and bone-marrow mesenchymal stromal cells.
During normal wound healing and inflammatory processes, local stromal cells change their phenotype to become
that of reactive stroma. Under certain conditions, however, tumor cells can co-opt these reactive stromal cells and
further transition them into tumor-associated stromal cells (TASCs). These TASCs express higher levels of proteins,
including alpha-smooth muscle actin, fibroblast activating protein, and matrix metalloproteinases, compared with
their normal, non-reactive counterparts. TASCs are also known to secrete many pro-tumorigenic factors, including
IL-6, IL-8, stromal-derived factor-1 alpha, vascular endothelial growth factor, tenascin-C, and matrix
metalloproteinases, among others, which recruit additional tumor and pro-tumorigenic cells to the developing
microenvironment. Here, we review the current literature pertaining to the origins of recruited host stroma,
contributions toward tumor progression, tumor-associated stromal cells, and mechanisms of crosstalk between
endogenous host stroma and tumor cells.
Keywords: Tumor-associated fibroblast, Cancer-associated fibroblast, Mesenchymal stem cell, Myofibroblast, Stroma,
Tumor microenvironment, Tumor-associated stroma, Alpha-smooth muscle actin, microRNA, Exosome, IL-6, MCP-1
Background
The tumor microenvironment is a heterogeneous popula-
tion of cells composed of tumor cells plus nearby endogen-
ous stromal cells recruited by the tumor [1]. It is becoming
well established that, during tumor progression, the tumor
cell “seed” co-evolves with the surrounding microenviron-
ment “soil” and that there is substantial crosstalk between
the various cell types which promote tumor growth and
development [2]. These supporting cells, recruited from
the local host stroma, promote extracellular matrix remod-
eling, cellular migration, neoangiogenesis, invasion, drug
resistance, and evasion of immunosurveillance through
production of various growth factors, chemokines, and
cytokines [2]. Though stromal composition is known to
vary between tumors [1], little is known about a) the
recruitment process by which tumor cells co-opt the host
stroma, or b) mechanisms of crosstalk between the host
stroma and tumor cells. Here, we review the current litera-
ture pertaining to the origins of recruited host stroma,
contributions toward tumor progression, tumor-associated
fibroblasts, and mechanisms of crosstalk between endogen-
ous host stroma and tumor cells.
Origins of tumor-recruited stroma
Interactions between the host stroma and tumor cells
play a critical role in tumor growth and progression. As
described by Dvorak [3], tumor stromal generation
exhibits many similarities to normal wound healing,
including neoangiogenesis, infiltration of fibroblasts and
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immune cells, and extensive remodeling of the extracellu-
lar matrix. Although these events facilitate the production
of the tumor bulk, tumors are strikingly heterogeneous in
their overall composition. This is primarily due to the
recruitment of nearby non-cancerous host stromal cells,
including bone-marrow mesenchymal stromal cells
(MSCs), adipocytes, and endothelial cells, that secrete a
plethora of mediators and growth factors for the tumor
that help facilitate tumor progression [3]. At the present,
several sources of host tissue have been identified as
targets for stromal cell recruitment by tumors: bone mar-
row, composed of mesenchymal cells, endothelial cells,
immune cells, adipocytes, and fibroblasts; connective
tissue, composed of fibroblasts and mesenchymal cells;
adipose tissue, composed of adipocytes; and blood vessels,
composed of pericytes and endothelial cells [1, 4]. In fact,
recent data have indicated that tumor-associated stroma
are a prerequisite for tumor cell invasion and metastasis
and arise from at least six distinct cellular origins: fibro-
blasts [5], pericytes [6], bone marrow MSCs [6], adipo-
cytes [4], macrophages [7], and immune cells [8] (Fig. 1).
Within the tumor microenvironment, there is substan-
tial evidence of cellular transdifferentiation, both from
stromal cell to stromal cell and from tumor cell to
stromal cell. The most frequently cited example is that
of fibroblast transdifferentiation into activated myofibro-
blast during formation of the reactive stroma [9]. Evidence
has been provided suggesting that this phenomenon is
both a transdifferentiation event [10] and a differentiation
event [9], depending on the circumstances. Other exam-
ples suggest evidence for pericyte transdifferentiation into
endothelial cells or fibroblasts, capable of forming tumor-
associated stromal cells (TASCs) [11]. On the other hand,
evidence suggests that cancer cells are capable of transdif-
ferentiation into stromal-like cells in order to facilitate
tumor progression. Scully et al. [12] found that glioblast-
oma stem-like cells were capable of transdifferentiation
into mural-like endothelial cells in order to promote
vascular mimicry. Furthermore, Twist 1 was found to
promote endothelial cell transdifferentiation of head and
neck cancer cells via the Jagged1/KLF4 axis in order to
enhance tumor angiogenesis [13]. Most recently,
Cerasuolo et al. [14] discovered that androgen-dependent
LNCaP cells cultured long-term in hormone independent
conditions permitted the transdifferentiation of prostate
cancer cells into a non-malignant neuroendocrine cell
phenotype, which were subsequently able to support the
growth of additional androgen-dependent prostate cancer
cells in the tumor microenvironment.
We and others have demonstrated that the cellular
origin of tumor-associated stroma may shape the pheno-
typic and biological characteristics of TASCs and, in
turn, contribute to the appearance of tumor-associated
stroma as a heterogeneous cell population with distinct
subtypes that express specific cellular markers [1]. These
characteristics are indicated in a hierarchical clustering
Fig. 1 Tumor-associated stromal cells arise from distinct cellular sources. Tumor-associated stromal cells (TASC) have been found to arise
from at least six distinct cellular origins: fibroblasts, pericytes, bone marrow MSCs, adipocytes, endothelial cells that have undergone an
endothelial mesenchymal transition (EndMT), or tumor cells that have undergone a epithelial to mesenchymal transition (EMT). Transition
of these cells occurs via soluble factors (SF), microRNAs (miR), exosomes (Exo), EMT, or EndMT and results in the formation of the TASC
subtypes: tumor-associated fibroblasts (TAF), cancer-associated adipocytes (CAA), or cancer-associated endothelial cells (CAEC)
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scheme in Fig. 2. At present, our laboratory has identified
at least five tumor-associated stroma subtypes of fibro-
blastic cells (data not published) ranging from “mese-
nchymal stem cell-like” (the least aggressive TASC as
evidenced by lack of remodeling of the extracellular
matrix and expression of MSC markers CD105, CD90,
CD73, and CD44) to the most aggressive “matrix
remodeling” subtype indicated by extensive tumor matrix
remodeling and increased expression of fibroblast
activating protein (FAP) and fibroblast specific protein-1
(FSP1), but decreased expression of alpha-smooth muscle
actin (alpha-SMA) [1, 15] (data not shown).
TASC subtypes
Nomenclature
Within the tumor microenvironment, several cell types have
been the focus of attention, including fibroblasts, myofibro-
blasts, pericytes, endothelial cells, macrophages, dendritic
cells, and other immune cells. Standard nomenclature for
the fibroblastic populations vary between tumor-associated
fibroblasts (TAFs), cancer-associated fibroblasts (CAFs),
carcinoma-associated fibroblasts (also collectively labeled
as CAFs), and tumor/cancer-associated stromal cells (TASC/
CASC). In the field, however, many of these terms are used
interchangeably, which can lead to confusion. In most cases,
at least one of several markers is used to characterize the
“reactive stroma”, frequently defined as TAF/CAF/TASC/
CASC. However, we propose that there is a distinct differ-
ence between the acronyms for cancer-associated fibroblast,
carcinoma-associated fibroblast, and tumor-associated fibro-
blast. To illustrate this difference, we provide the definitions
of the three words, cancer, carcinoma, and tumor: 1) cancer
refers to a disease caused by cells that are not normal and
that can spread to one or many parts of the body; 2) carcin-
oma refers to a malignant tumor of epithelial origin; and 3)
tumor refers to an abnormal benign or malignant new
growth of tissue that possesses no physiological function and
arises from uncontrolled, usually rapid cellular proliferation
[16]. From these definitions, we postulate the following: 1) a
cancer-associated fibroblast is one that is exposed to disease
(cancer) but can be found in any location within the body
associated with that disease or its spread (For the remainder
of this publication, the term "CAF" refers to "Cancer-Associ-
ated Fibroblast."); 2) a carcinoma-associated fibroblast is one
that can be found in direct contact with a tumor of epithelial
origin, thus excluding hematological malignancies, sarcomas,
germ-cell tumors, and all other non-epithelial tumors; and
3) a tumor-associated fibroblast is one that can be found in
direct contact with, or immediately adjacent to, a tumor.
Furthermore, we propose that TAFs, CAFs, and other
tumor-associated cells can all be classified under the heading
of “tumor-associated stromal cells” (TASCs).
TAFs/CAFs
Fibroblasts regulate the structure and function of healthy
tissues via extracellular matrix remodeling and transient
tissue repair during wound healing [17]. However, a grow-
ing body of evidence demonstrates that fibroblasts are key
players in tumorigenesis and constitute the majority of
stromal cells within a tumor, especially in breast, prostate,
and pancreatic cancers [17]. TAFs/CAFs are activated
fibroblasts that share many similarities with normal fibro-
blasts found during wound healing and inflammation [18].
During tumor progression, TAFs/CAFs show increased
rates of proliferation, promote tumor growth via a variety
of mechanisms, and mediate therapeutic resistance [18].
In a study by Erez et al. [19], TAFs/CAFs in the tumor
stroma promoted sustained inflammation via increase of
inflammatory cytokines, neoangiogenesis, and macro-
phage recruitment, enhancing tumor growth. TAFs/CAFs
are also known to enhance angiogenesis via secretion of
factors that stimulate pericytes and endothelial cells and
have also been implicated in extracellular matrix remodel-
ing [2]. In the past, MSC- and fibroblast-derived TAFs/
CAFs have been defined by a specific subset of markers,
including alpha-SMA, tenascin C, fibroblast-specific
protein-1, fibroblast activing protein, and neural-glial anti-
gen [20]. However, the different sources of TAFs/CAFs,
cellular heterogeneity of the tumor microenvironment,
similarity of TAFs/CAFs to normal host fibroblasts, as well
as inconsistencies in nomenclature make it difficult to dis-
tinguish TAFs/CAFs in the tumor stroma from other cell
types expressing similar markers. Thus, there is a need for
a well-defined list of TASC subtypes, complete with their
cellular markers as well as tissue of origin.
Fig. 2 Continuum of tumor-associated stromal cell phenotypes. We
propose the existence of at least five tumor-associated fibroblast
subtypes as distinguished by specific markers during the course of
tumor progression: MSC-like is the least aggressive as evidenced by
lack of remodeling of the extracellular tumor matrix and expression
of MSC markers CD105, CD90, CD73, and CD44; Endothelial-like cells,
which express CD31; Myofibroblast-like, which are more aggressive
“activated” stroma and express alpha-smooth muscle actin (alpha
SMA) and tenascin C (TnC); Pericyte-like, which express NG2 and
platelet-derived growth factor receptor (PDGFr); and Matrix-remodel-
ing, which are the most aggressive subtype indicated by extensive
tumor matrix remodeling, increased expression of FAP and FSP1,
and decreased expression of alpha-SMA
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Cancer-associated adipocytes
In addition to CAFs/TAFs, there is growing evidence to
support a TASC subtype derived exclusively from adipose
tissue called cancer-associated adipocytes (CAAs) [4]
(Fig. 1). Found at the invasive front of tumors, CAAs have
been shown to express factors involved in matrix remodel-
ing, invasion and survival of cancer cells, as well as induce
epithelial to mesenchymal transition (EMT) [4]. In
particular, Wang et al. [21] discovered that CAAs
produced increased amounts of insulin-like growth factor
binding protein-2 (IGFBP-2) compared with their normal
adipocyte counterparts and that this CAA-derived IGFBP-
2 resulted in enhanced migration and metastasis of
human breast cancer cells both in vitro and in vivo.
Furthermore, Dirat et al. [22] showed that mature adipo-
cytes co-cultured with breast cancer cells increase their
expression of matrix metalloproteinases (MMP-11) as well
as the pro-inflammatory cytokines interleukin (IL)-6 and
IL-1β. And Nieman et al. [23] demonstrated that co-
culture of human adipocytes with ovarian cancer cells led
to increased adipocyte production of IL-8 and fatty acid-
binding protein 4, which were found to promote the hom-
ing, migration, and invasion of ovarian cancer cells. Co-
culture of the adipocytes and ovarian cancer cells was add-
itionally found to stimulate lipolysis in the adipocytes as
well as β-oxidation in the ovarian cancer cells, suggesting
that the CAAs may additionally be an energy source for
the cancer cells. These data as a whole suggest that cross-
talk between adipocytes and cancer cells result in the for-
mation of CAAs, which promote the homing and
metastasis of cancer cells as well as participate in the de-
velopment of the tumor microenvironment.
Cancer-associated endothelial cells
In addition to CAFs/TAFs and CAAs, an endothelial
cell-derived TASC subtype is also known to play an
important role in tumor cell growth and invasion. Data
have shown that proliferating endothelial cells derived
from the bone-marrow undergo an endothelial-to-
mesenchymal transition (EndMT) in the presence of tumor
growth factor (TGF)-beta, converting the endothelial cells
into fibroblast-like cells [23] (Fig. 1). These newly derived
cancer-associated endothelial cells (CAECs) exhibit down-
regulation of endothelial cell markers CD31 and up-
regulation of the TAF/CAF markers FSP1 and alpha-SMA
[23]. Interestingly, breast cancer treatment with chemother-
apeutic agents has been found to increase CAEC-derived
production of tumor necrosis factor (TNF)-alpha, causing
an increase in production of CXCL1/2 via nuclear factor
(NF)-kappaB by the cancer cells [24]. Increased CXCL1/2
production both attracts myeloid cells and causes them to
increase their production of S100A8/9 proteins, which in-
crease breast cancer cell survival and chemoresistance [24].
Other groups have described a type of cancer-activated
circulating endothelial cell that was found to promote
tumor cell metastasis and protect tumor cells in circulation
from targeted therapeutics via chaperoning cancer cells to
distant sites [25]. Thus, these results suggest that CAECs
are key players in cancer cell evasion of immunosurveil-
lance and enhanced chemoresistance.
Tumor-associated immune stroma
Immune cells have also been identified as contributing to
the tumor-associated microenvironment via dysregulation
of immune-mediated responses. Macrophages, dendritic
cells, natural killer (NK) cells, myeloid-derived suppressor
cells, and regulatory T cells (Tregs) have all been shown to
contribute toward the polarization of a pro-tumorigenic
microenvironment due to their functional responses to
contextual cues within the tumor niche. Briefly, tumor-
associated macrophages (TAMs) are a distinct M2-
polarized macrophage population that promote immune-
suppression, pro-angiogenesis, and tumor cell migration
and invasion [7]. Targeting of TAMs leads to reduced
tumor cell invasion, angiogenesis, and metastasis, as well
as enhance the antitumor activity of chemotherapeutics
[26]. Myeloid-derived suppressor cells have been shown to
differentiate into TAMs and dendritic cells during tumor
progression and contribute to tumorigenesis through
enhancement of tumor immune evasion, matrix remodel-
ing, and tumor cell EMT [27]. Dendritic cell activity is
frequently dysregulated in cancer, leading to reduction in
mature dendritic cell numbers, abnormal maturation (and
increased numbers of immature dendritic cells with
tolerogenic and immunosuppressive capabilities), and sup-
pressed differentiation [28]. Two distinct NK subpopula-
tions, called tumor-infiltrating natural killer cells (TINKs)
and tumor-associated natural killer cells (TANKs), have
been described in tumor tissues [29]. These NK subpopu-
lations exhibit altered cytokine expression, including
increased levels of pro-angiogenic factors such as vascular
endothelial growth factor (VEGF) and stromal-derived
factor-1 (SDF-1), leading to sustained angiogenesis and
tumor progression [30]. Finally, Tregs have been shown to
play a causal role in tumor progression via infiltration of
tumor tissue and reduction of the antitumor immune
response [31]. Furthermore, Facciabene et al. [32] recently
reported that Tregs produced VEGF-A, leading to
sustained angiogenesis in a mouse model of ovarian
cancer. Taken together, this evidence suggests that con-
textual responses of immune cells within the tumor
stroma helps to drive tumor progression.
TASCs and soluble factor signaling within the tumor
microenvironment
As previously described, TASCs have been found to secrete
a variety of soluble factors that enhance formation of the
tumor microenvironment. These factors include pro-
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inflammatory cytokines (IL-6, IL-8, IL-1β, to name a few),
matrix metalloproteinases, and growth factors, among
others. In the next few paragraphs, we focus on a small
sampling of these TASC-derived factors as examples (the
pro-inflammatory cytokines and chemokines IL-6, CXCL1,
IL-1β, and TNF-alpha) and discuss their contribution
towards signaling in the tumor microenvironment and
stimulation of additional TASC-derived factors in detail.
IL-6
TASCs promote tumor growth in the microenvironment
via secretion of cytokines and chemokines. IL-6, specific-
ally, is a pro-inflammatory cytokine known to alter
stromal cell function, migration, and EMT in the tumor
microenvironment [33]. Importantly, Osuala et al. [34] de-
termined that TAFs, in particular, produce large amounts
of IL-6, which promotes the growth and proliferation of
MCF10.DCIS ductal carcinoma in situ (DCIS) breast can-
cer cells. Co-culture of TAFs plus MCF10.DCIS cells led
to an increase in tumor size, development of multicellular
structures, and formation of branch-like connections
composed primarily of tumor cells [34]. The authors
additionally found that DCIS cells preferentially migrate
towards TAFs and form heterocellular contacts with TAFs
driven by an IL-6 expression gradient at the invasive edge
of DCIS tumor spheroids. Blockade of IL-6 reduced TAF-
stimulated DCIS growth and proliferation and reduced
the formation of TAF–cancer cell interconnections [34].
In addition to being overexpressed by TAFs, IL-6 is also
a key regulator of TAF transition from normal fibroblasts.
Lee et al. [35] determined that exposure to IL-6 was suffi-
cient to induce Twist1 expression in primary human
gastric fibroblasts and convert them into TAFs via phos-
phorylation of STAT3. Similarly, Giannoni et al. deter-
mined that prostate cancer-derived IL-6 induces the
activation and increased expression of FAP by normal
human prostate fibroblasts, which, in turn, leads to
autocrine-activated fibroblast production of IL-6 and in-
creased prostate cancer cell invasiveness via EMT [36].
Yeh et al. [37] additionally found that the co-culture of
normal fibroblasts with bladder cancer cells increased both
total IL-6 expression and bladder cancer invasiveness.
Blockade of total IL-6 reduced the amount of fibroblast-
mediated bladder cancer invasion, suggesting that IL-6 in
the tumor microenvironment is necessary for TAF activa-
tion, which subsequently regulates cancer cell invasion
[37]. Finally, IL-6 mediated signaling has also been shown
to contribute to TAF-triggered therapeutic resistance.
Upregulation of mammalian target of rapamycin
(mTOR)–4E-BP-1 signaling has been shown to be highly
activated in primary human TAFs isolated from pancreatic
ductal adenocarcinoma [38]. When mTOR–4E-BP-1
signaling is inhibited, the production of alpha-SMA-
positive TAFs is substantially reduced, as is the production
of downstream secreted proteins, including IL-6. In mur-
ine xenografts composed of either MIA PaCa-2 or Panc-1
human pancreatic cancer cells plus CAFs, pre-treatment
of TAFs with pasireotide (an inhibitor of the mTOR–4E-
BP-1 pathway) followed by treatment with gemcitabine led
to a reduction in tumor growth and chemoresistance [38].
Further experiments revealed that pasireotide plus gemaci-
tabine bi-therapy was synergistic and led to gemcitabine-
induced cancer cell apoptosis. Tumor collagen deposition
was also reduced, suggesting that pasireotide may act as
an anti-fibrotic agent [38].
CXCL1 (GRO-alpha)
In addition to IL-6, TAF overexpression of CXCL1 (GRO-
alpha) has been recently shown to induce tumor cell inva-
sion and enhance chemotherapeutic resistance. CXCL1 is
known to promote breast tumor growth, metastasis, as well
as chemotherapeutic resistance, is associated with poor
patient prognosis, and is also dysregulated in melanoma,
bladder cancer, and prostate cancer [39]. Increased expres-
sion of CXCL1 in TAFs has additionally been correlated
with poor patient outcome and is associated with
decreased expression of TGF-beta [39]. Fang et al. [39]
determined that CXCL1 expression was decreased in
breast cancer-derived TAFs upon treatment with TGF-
beta, via Smad2/3 signaling. Regulation of Smad2/3 was
also associated with decreased expression of hepatocyte
growth factor (HGF), which also decreased CXCL1 expres-
sion through c-Met receptor signaling. Additionally, HGF/
c-Met signaling was found to be necessary for activation of
NF-kappa-B, and thus CXCL1 expression, in TAFs [39].
TNF-alpha and IL-1beta
The activation of TAFs from MSCs in breast cancer,
specifically, has been shown to occur via high levels of
TNF-alpha and IL-1beta in the tumor microenvironment.
These chemokines are also known to regulate the expres-
sion of the pro-inflammatory cytokines MCP-1 (monocyte
chemotactic protein-1; CCL2), IL-8 (CXCL8), and
RANTES (CCL5) in breast cancer [40]. Katanov et al. [40]
discovered that, when treated with TNF-alpha and IL-
1beta, MSCs and TAFs derived from human breast cancer
patients increased their production of MCP-1, RANTES,
and IL-8. MSC treatment with TNF-alpha also resulted in
increased MCP-1 expression, which subsequently induced
chemoattraction of monocytic immune cell infiltrate, in-
cluding tumor-associated macrophages [40]. Similarly,
Taguchi et al. [41] determined that TAFs co-cultured with
breast cancer cells increase their production of TNF-alpha,
leading to increased production of metalloproteinase
(MMP)-9 and neovascularization in the tumor microenvir-
onment. Other groups have found that expression of IL-
1beta by immune cells induces the transition of normal
fibroblasts to TAFs. Once activated, TAFs then increase
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their production of IL-1beta, which in turn leads to the
activation of the phosphoinositide 3-kinase (PI3K) and
NF-kappaB pathways, both of which enhance tumor
angiogenesis and growth [19].
TASCs and microRNAs
microRNA dysregulation in TAFs
microRNAs (miRs) are a class of small, single-stranded,
noncoding RNAs that are involved in gene expression,
stem cell maintenance, cell fate determination, and devel-
opmental processes [42]. Dysregulation of miR expression
has been implicated in tumor cell promotion, migration,
and invasion [42]. Moreover, miR expression has been
recently found to be altered in TAFs, correlating with
increased tumor aggressiveness and poor patient progno-
sis. In a study performed by Kadera et al. [43], the UCLA
153 pancreatic ductal adenocarcinoma patient tissue
microarray and 23 patient-matched lymph node metasta-
ses were analyzed via in situ hybridization for the expres-
sion of miR-21, a miR known to be involved in cancer
progression. The authors discovered that miR-21 was
upregulated in the TAFs of 78 % of patient tumors.
Among these, high miR-21 expression was found to be
correlated with decreased overall patient survival as well
as patient lymph node invasion and metastasis [43].
Furthermore, activation of TASCs has been suggested
to be regulated by miR-21/miR-221 in pancreatic cancer.
Specifically, Ali et al. [44] analyzed the expression of
miR-21/miR-221 in the conditioned medium of both
human TAF cells and pancreatic stellate cells and
compared it to the expression of miR-21/miR-221 in the
conditioned medium of human pancreatic cell lines
COLO-357 and MIAPaCa-2. Expression levels of miR-
21/miR-221 were found to be higher in both the TAF
and pancreatic stellate cells compared with MIAPaCa-2
pancreatic cancer cells or normal human stellate cells.
Upon co-culture with TAF or pancreatic stellate cells,
COLO-357 pancreatic cancer cells exhibited increased
pancreatosphere formation and clonogenicity [44].
Dysregulation of miRs has also been found to impact
common signaling cascades in TAFs, such as the
mitogen-activated protein kinase (MAPK)/ERK pathway.
Miller et al. [45] identified a novel miR signature associ-
ated with hyperactive MAPK signaling that was signifi-
cantly correlated with a poor response to hormone
therapy in both luminal A and B estrogen receptor (ER)-
positive breast cancer subtypes. In a follow-up study, the
authors determined that TAF-derived miR221/222
elicited breast cancer cell ER repression and, thus,
decreased therapeutic response [46]. Furthermore, miR-
15a and miR-16, which regulate cell cycle and anti-
apoptotic genes, have been shown to be downregulated
in the stroma of human prostate tumors [47]. In a study
by Musumeci et al. [47], downregulation of miR-15a and
miR-16 in the TAFs of prostate cancer cells was found
to promote both prostate cancer cell growth and pro-
gression. Enhanced expression of miR-15a and -16 in
TAFs decreased tumor cell proliferation and reduced the
tumor-supportive capacity of the TAFs both in vitro and
in vivo, suggesting that these miRs regulate the pro-
tumorigenic properties of tumor-associated stroma.
Recent evidence suggests that epigenetic gene silencing
due to CpG island methylation may be responsible for
miR dysregulation in TAFs. A study by Li et al. [33] inves-
tigated whether DNA hypermethylation of a miR-149 was
correlated with altered gene expression in gastric cancer.
The authors identified a GC-rich region upstream of the
miR-149 start site which was hypermethylated in TAFs
compared with normal fibroblasts. Furthermore, the au-
thors found that prostaglandin E2, an inflammatory medi-
ator in cancer, triggered DNA methylation of the miR-149
gene, leading to a reduction in miR-149 expression [33].
Interestingly, while hypomethylation of miRs is frequent in
cancer [48], no examples of hypomethylation as a possible
mechanism of miR dysregulation in TAFs were found.
miRs are capable of transitioning normal fibroblasts into TAFs
In addition to miR dysregulation in TAFs, miRs have
also been shown to be involved in TAF transition from
MSCs. Pang et al. [49] found that, upon delivery of
microvesicles expressing miR-155, normal pancreatic
murine fibroblasts converted into a TAF-like cell. In
addition, the authors determined that microvesicles
derived from pancreatic cancer cells overexpressed miR-
155, indicating that pancreatic cancer cells may co-opt
normal fibroblasts, transitioning them into TAFs via
production of microvesicles containing miR-155 [49]. In
a similar study, normal human omental fibroblasts were
triple transfected with anti-miR-31, anti-miR-214, and
pre-miR-155 [50]. This resulted in enhanced fibroblast
migration, invasion, and colony formation, suggesting
fibroblast transformation into TAFs. On the other hand,
when ovarian cancer cell-associated fibroblasts were
triple transfected with pre-miR-31, pre-miR-214, and
anti-miR-155, the fibroblasts exhibited reduced migra-
tion, reduced invasion, as well as reduced colony forma-
tion [50]. Dysregulation of miR-210 has also been shown
to convert fibroblasts into TAF-like cells. In a study by
Taddei et al. [51], overexpression of miR-210 in human-
derived fibroblasts was found to transition the fibro-
blasts into TAF-like cells able to promote prostate
cancer progression via EMT as well as support prostate
tumor angiogenesis.
miRs are involved in the recruitment and modification of
stromal cells by tumor cells
In addition to being involved in the transition of fibro-
blasts to TAFs, miRs have been found to promote stromal
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cell recruitment by tumor cells in the microenvironment.
In one study, the miR pair miR-126/miR-126* was found
to suppress MSC recruitment into the tumor stroma of
breast cancer cells [52]. This phenomenon also led to
inhibition of lung metastases in a mouse xenograft model
via miR-126/miR-126* inhibition of stromal-derived
factor-1 alpha and CCL2 [52]. In another study, miR-149
was identified as a critical driver for the recruitment of
normal fibroblasts in the tumor microenvironment in a
human and mouse model of gastric cancer. Hypermethyla-
tion of the miR-149 promotor via cyclooxygenase-2/pros-
taglandin E2 and IL-6-mediated signaling led to repression
of miR-149 expression in both human and murine fibro-
blasts in vitro and in vivo. Reduced expression of miR-149
was then found to promote gastric cancer progression via
increased fibroblast activation and tumor cell EMT [33].
TAFs and exosomes
Exosomes are microvesicles ranging in size from ~30–200
nm that are produced by cells and contain the molecular
constituents of their cell of origin, including protein,
RNA, and DNA [46]. Recent literature has focused on
exosome production by TAFs and the role that these
microvesicles play in signaling within the tumor micro-
environment. In a study by Shah et al. [46], conditioned
media from TAFs derived from three different PAM50
subtypes of breast cancer (basal, Her2+, and luminal A
subtypes) were analyzed for the presence of exosomes.
Transmission electron microscopy as well as nanoparticle
tracking analysis confirmed the presence of exosomes pro-
duced by the TAFs as well as the uptake of these exosomes
by ER-positive MCF-7/ltE2-negative breast cancer cells.
TAF-derived exosomal uptake resulted in ER repression in
ER-positive breast cancer cells, corresponding with
increased disease recurrence and reduced overall patient
survival [46]. Furthermore, Luga and Wrana [53] deter-
mined that exosomes in the conditioned media of both L-
cell fibroblasts as well as TAFs derived from human breast
cancer tissue stimulated the protrusive activity, motility,
and lung metastasis via the Wnt-planar cell polarity path-
way of MDA-MB-231 and SUM-159PT breast cancer
cells, among others. Moreover, in subsequent studies, the
authors showed that, when taken up by breast cancer
cells, fibroblast-derived exosomes co-localize with breast
cancer cell-derived Wnt11 within endocytic vesicular
structures. This action was found to be important for
enhancing exosome-stimulated motility in MDA-MB-231
and SUM159PT breast cancer cells [54].
Exosomes derived from cancer cells induce the transition of
stromal cells into TAFs
Exosomes derived from solid tumor cells are known to
be involved in inflammation, tumor progression, angio-
genesis, and metastasis [53]. It is becoming increasingly
evident that exosomes derived from tumor cells also
impact the local stroma, driving production of the tumor
microenvironment. This same phenomenon is evident in
leukemias, where exosomes have been found to be
produced by chronic lymphocytic leukemia (CLL) cells.
Paggetti et al. [55] determined that exosomes produced
by CLL cells were taken up by local MSCs as well as
endothelial cells both ex vivo and in vivo. These CLL-
derived exosomes were found to contain miRs and pro-
teins, which resulted in an inflammatory phenotype in
the endothelial cells and MSCs resembling that of TAFs.
Upon uptake of the CLL-derived exosomes, both the
MSCs and endothelial cells exhibited increased prolifera-
tion, migration, as well as production of inflammatory
cytokines. The exosome-incorporated endothelial cells
specifically showed increased tumor angiogenesis both
ex vivo and in vivo, suggesting that CLL-derived
exosomes promote tumor progression via transitioning
of local stromal cells into TAF-like cells [55].
Exosomes produced by cancer cells under hypoxic
conditions have also been shown to transition stromal
cells into TAFs. In a study by Ramteke et al. [56], human
prostate cancer LNCaP and PC3 cells were exposed to 1
% O2 or 21 % O2 conditions and their exosomes isolated
from the derived-conditioned media. Exosomes pro-
duced under conditions of 1 % O2 were found to be
smaller in size via nanoparticle tracking analysis as well
as exhibited higher levels of CD63, CD81, and MMPs,
among others, compared with exosomes produced under
conditions of 21 % O2. When LNCaP and PC3 prostate
cancer cells were co-cultured with exosomes produced
under conditions of 1 % O2, the motility, invasiveness,
and prostasphere formation of the prostate cancer cells
was increased, as well as alpha-SMA expression in
nearby stromal cells, resulting in formation of TAF-like
cells [56]. While the authors considered 1 % O2 to be
hypoxic and 21 % O2 to be normoxic conditions, it
should be noted that these values are at extreme ends of
the scale. Even though it is difficult to put exact figures
on tissue levels, it is most widely accepted that oxygen
tension in the range of 1–5 % O2 is generally considered
“hypoxic” and oxygen tension in the range of 10–21 %
O2 is considered “normoxic”. Oxygen tensions above 21
% are typically considered “hyperoxic” [57].
TAFs, exosomes, and therapeutic resistance
Data have shown that TAFs play significant roles in the
therapeutic sensitivity of tumors and that therapeutic tar-
geting of TAFs results in increased chemotherapeutic sensi-
tivity. A recent study by Hu et al. [58] discovered that, in
addition to directly increasing chemoresistance themselves,
TAFs are also capable of priming cancer stem cells via
TAF-derived exosomes, which further decrease drug sensi-
tivity in colorectal cancer. Specifically, CD133+ colorectal
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cancer-derived stem cells were treated with TAF-derived
conditioned medium (CM) derived from a human patient
with Duke B colorectal adenocarcinoma. Proliferation,
tumor size, clonogenicity, and chemotherapeutic resistance
to conventional agents 5-fluorouracil or oxaliplatin were all
found to be increased in the TAF-CM treated colorectal
cancer-derived stem cells. Further investigation of the CM
revealed that CD81+ exosomes were present and that these
exosomes were acting on the colorectal cancer-derived
stem cells via Wnt3a signaling. Blockade of exosome bio-
genesis with GW4869 markedly decreased colorectal
cancer-derived stem cell therapeutic resistance to both 5-
fluorouracil and oxaliplatin, suggesting that fibroblast-
derived exosomes act on colorectal cancer-derived stem
cells via the Wnt3a signaling pathway to increase drug
resistance [58]. Thus, this evidence as a whole suggests that
exosomes mediate reciprocal crosstalk between tumor-
associated stromal cells and cancer cells during formation
of the tumor microenvironment.
Conclusions
It is becoming increasingly evident that the tumor micro-
environment is a heterogeneous mixture of tumor cells
plus endogenous host stroma that co-evolve during the
course of disease progression. Importantly, cells of the
stromal compartment of tumors, which include MSCs,
fibroblasts, endothelial cells, pericytes, adipocytes, and
immune cells, are increasingly being recognized as crucial
players in the development of the tumor microenviron-
ment, metastasis, immune infiltration and inflammation,
and chemotherapeutic resistance (Table 1). Furthermore,
one looming question that has yet to be addressed is the
idea of a hierarchy, or continuum of TASCs during the
transition from “normal” cell to reactive stromal cell.
Table 1 Sources of stromal cell regulation in the tumor microenvironment
Dysregulation
in TASCs
Regulator of
TAF transition
Regulator of stromal
cell recruitment
Mediates TASC-induced
therapeutic resistance
IGFBP-2 [21] - - -
MMP-11 [22] - - -
IL-6 [34, 35] [34–37] [35] [34, 38]
IL-8 [40] - - -
IL-1beta [40] [22, 31] - -
TNF-alpha [40, 41] [31] - -
NF-kappaB [24] - - -
TGF-beta [39] - - -
CXCL1/2 [24, 39] - - [24, 39]
FAP [35] - - -
MCP-1 [40] - - -
Twist1 - [13, 35] - -
miR-21 [43] [44] - -
miR-221/222 [44] [44] - [46]
MAPK/ERK [45] - - -
miR-15a/16 [47] - - -
miR-210 [51] [51] - -
Exosomes [53–56] - - [58]
mTOR-4E-BP-1 - - - [38]
miR-126/126* - - [52] -
miR-149 - - [33] -
miR-155 - [49, 50] - -
miR-31 - [50] - -
miR-214 - [50] - -
Soluble factors produced by both the cancer cells and TAFs promote homing, migration, and invasion of tumor cells; regulate stromal cell recruitment and TAF
transition; and mediate therapeutic resistance. MicroRNAs (miRs) facilitate stromal cell recruitment by cancer cells, formation of TAFs, as well as tumor growth and
development. Exosomes orchestrate TAF-mediated chemotherapeutic resistance within the tumor, TAF formation, and TAF-induced cancer cell invasion and
metastasis. The sources of these factors are listed. The dash indicates that we were unable to find evidence from the literature, within page constraints, of factor
involvement in the indicated type of stromal cell regulation
miR-126* is the complement of miR-126. By all accounts in the literature, miR-126* is the standard nomenclature of the microRNA.
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During this evolution, are different markers turned on/off
along the way? Our work suggests that TASCs are com-
posed of discreet subpopulations, identified by specific
markers, indicating different “stages” of TASC evolution
during disease progression [1] (unpublished data) (Fig. 2).
And yet, within these “stages”, it is still unknown if the
markers expressed during the course of transition are
impacted by the cell of origin (i.e., different transition
markers for fibroblasts transitioned to TAFs versus adipo-
cytes transitioned to CAAs)? Once determined, is it pos-
sible to use these markers to identify TASCs in patient
biopsies? As is evidenced by the various roles TASCs play
in tumor progression, it is highly probable that any TASC
population is a heterogeneous mixture of not only reactive
stroma (i.e., TAFs plus CAECs), but also unactivated by-
stander normal cells (i.e., fibroblasts and endothelial cells).
With many of the same markers being expressed by “acti-
vated” stroma as well as normal cells, what criteria will be
used in the clinic to determine the margin of the tumor
microenvironment during excision? Moreover, it is possible
that this stromal cell population evolves with the tumor,
possibly changing composition during tumor progression.
How will the evolution of the stromal cell population and,
conversely, additional stromal cell recruitment during the
evolution of tumor progression be prevented clinically?
And, how will cell-derived factors, including miRs and
exosomes, be specifically targeted to prevent additional
endogenous stromal cell recruitment, transition, or thera-
peutic resistance? Given the extensive crosstalk between
tumor cells, local endogenous stroma, and tumor-
associated stroma, personalized multi-modal therapeutic
strategies need to be developed that target not only the
tumor bulk but also the tumor-associated stromal compart-
ment and affiliated cell-derived factors described herein.
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